Answers are grounded in this paper and cite their sources.
Biochemical assay demonstrates direct profiling of cannabinoid receptor allosteric modulators in vitro, indicating dual-site binding for cannabidiol.
Allosteric modulation of cannabinoid receptor type 1 (CB 1 R) offers a promising alternative to conventional therapeutic approaches using orthosteric ligands (OLs). Currently, CB 1 R allosteric modulators (AMs) are characterized based on their ability to modulate binding or functional response of OLs, preventing isolation of individual contributions by allosteric and orthosteric ligands. Herein, we develop the first allosteric fluoroprobe and attendant FRET‐based assay allowing for the direct profiling of CB 1 R AMs without coincubation with an OL. Our allosteric tracer enables differentiation of allosteric and orthosteric ligands as well as their pharmacological profiling at CB 1 R. The utility of this work is highlighted by addressing ambiguities surrounding the binding of cannabidiol (CBD). CBD was found to interact with both allosteric and orthosteric sites of CB 1 R with comparable affinity (p K i =5.34 and 5.67, respectively).
No takes yet. Share an insight, caveat, or question.
Kosar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: